



Divi's Laboratories Limited

Date: 08 August, 2020

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

Sub: Outcome of Board Meeting – Submission of Unaudited financial results for the quarter ended 30 June, 2020–reg

Ref: Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Further to our intimation dated 29 July, 2020, we would like to inform that the Board of Directors of the Company at its meeting held on Saturday, 08 August, 2020 has approved the Unaudited Financial Results for the quarter ended 30 June, 2020.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Statement of Standalone Unaudited Financial Results for the quarter ended 30 June, 2020 and Limited Review Report of the Statutory Auditors thereon.
2. Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June, 2020 and Limited Review Report of the Statutory Auditors thereon.
3. Press Release on the Financial Results of the Company.

The Board meeting commenced at 10:35 Hrs and concluded at 12.15 Hrs.

Hrs . This is for your information and records.

Thanking You,
Yours faithfully,
For Divi's Laboratories Limited


M. Satish Choudhury
Company Secretary & Compliance Officer



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislabs.com, Website : www.divislabs.com

DIVI'S LABORATORIES LIMITED


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs.in lakhs)


S. No.	Particulars	Quarter ended			Year ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)*	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Income				
	Revenue from operations	170996	137624	113992	531057
	Other income	1787	7652	3163	18986
	Total income	172783	145276	117155	550043
2	Expenses				
	a) Cost of materials consumed	45949	54224	50398	218266
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	17719	(3236)	(5025)	(9410)
	d) Employee benefits expense	18035	16973	13795	60836
	e) Depreciation and amortization expense	5597	4954	4381	18595
	f) Finance costs	18	40	32	606
	g) Other expenses	19395	24799	16963	79821
	Total expenses	106713	97754	80544	368714
3	Profit before exceptional items and tax (1-2)	66070	47522	36611	181329
4	Exceptional items	-	-	-	-
5	Profit before tax (3-4)	66070	47522	36611	181329
6	Tax expense				
	a) Current tax	18648	5309	9365	38779
	b) Deferred tax	(1803)	3033	511	5279
	Total tax expense	16845	8342	9876	44058
7	Profit for the period (5-6)	49225	39180	26735	137271
8	Other comprehensive income:				
	a) Items that will not be reclassified to Profit or Loss:				
	(i) Remeasurement of post-employment benefit obligation	(38)	(780)	40	(680)
	(ii) Income tax relating to the above	13	185	(10)	159
	Total other comprehensive income (i-ii)	(25)	(595)	30	(521)
9	Total comprehensive income for the period ((7+8)	49200	38585	26765	136750
10	Paid-up Equity Share Capital (Face Value: Rs.2/- per share)	5309	5309	5309	5309
11	Other equity excluding revaluation reserve				726360
12	Earnings per Share (Face Value Rs.2/- each) (not annualized)				
	a) Basic (Rs.)	18.54	14.76	10.07	51.71
	b) Diluted (Rs.)	18.54	14.76	10.07	51.71

Notes:

- The above Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2020 ("Statement") is prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 8th August, 2020. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS 108.
- The Company does not have any discontinued operations and the Profit for the period represents Profits from continuing operations only.
- The Company has not experienced any significant impact on its operations, supply chain and recovery of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Company will continue to closely monitor for any material changes to future economic conditions.



(Handwritten Signature)



DIVI'S LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020

5. Current Tax Expense includes adjustment of tax reversals of earlier years amounting to Rs.665 lakhs.
6. Forex gain included in Other Income / (loss) included in Other Expenses for the respective periods is as given below:

	Quarter Ended			Year Ended
	30.06.2020 Rs. in lakhs	31.03.2020 Rs. in lakhs	30.06.2019 Rs. in lakhs	31.03.2020 Rs. in lakhs
Forex gain /(loss)	535	5716	(596)	8204

7. *Figures for the quarter ended 31.03.2020 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year.
8. Figures for the previous year/period are regrouped or reclassified wherever necessary to conform to current period's classification.

Place: Hyderabad
Date: 8th August, 2020



For Divi's Laboratories Limited

Murari K. Divi
Dr. Murari K. Divi
Managing Director



Price Waterhouse Chartered Accountants LLP

To
The Board of Directors
M/s Divi's Laboratories Limited
Divis Towers, 1-72/23(P)/303
Cyber hills, Gachibowli
Hyderabad, 500032

1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended June 30, 2020 which are included in the accompanying Statement of Standalone Unaudited financial results for the quarter ended June 30, 2020 (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been stamped by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: FRN 012754N/N500016



Sunit Kumar Basu
Partner
Membership Number 55000

UDIN: 20055000AAAAEV7484

Place: Hyderabad
Date: August 08, 2020

Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

DIVI'S LABORATORIES LIMITED


**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30th JUNE, 2020**

(Rs. in lakhs)

S. No.	Particulars	Quarter ended			Year ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)*	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Income:				
	Revenue from operations	173047	138971	116288	539442
	Other income	1733	7673	3032	18963
	Total income	174780	146644	119320	558405
2	Expenses				
	a) Cost of materials consumed	46427	54568	50992	219841
	b) Purchases of stock-in-trade	379	993	123	1611
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	17178	(4020)	(5882)	(10598)
	d) Employee benefits expense	18390	17314	14086	62105
	e) Depreciation and amortization expense	5620	4978	4383	18624
	f) Finance costs	23	44	32	610
	g) Other expenses	20665	25671	18255	84266
	Total expenses	108682	99548	81989	376459
3	Profit before exceptional items and tax (1-2)	66098	47096	37331	181946
4	Exceptional items	-	-	-	-
5	Profit before tax (3-4)	66098	47096	37331	181946
6	Tax expense				
	a) Current tax	18785	5388	9568	39279
	b) Deferred tax	(1893)	2885	519	5013
	Total tax expense	16892	8273	10087	44292
7	Profit for the period (5-6)	49206	38823	27244	137654
8	Profit for the period attributable to:				
	Shareholders of the Company	49206	38823	27244	137654
	Non-controlling interest	-	-	-	-
9	Other comprehensive income:				
	a) Items that will not be reclassified to profit or loss:				
	i) Remeasurement of post-employment benefit obligations	(38)	(780)	40	(680)
	ii) Income tax relating to the above	13	185	(10)	159
	b) Items that will be reclassified to Profit or Loss:				
	i) Exchange differences in translating the financial statements of a foreign operation	32	280	**	618
	ii) Income tax relating to the above	(3)	(25)	-	(62)
	Total other comprehensive income	4	(340)	30	35
10	Total other comprehensive income for the period attributable to:				
	Shareholders of the company	4	(340)	30	35
	Non-controlling interest	-	-	-	-
11	Total comprehensive income for the period (7+9)	49210	38483	27274	137689
12	Total comprehensive income for the period attributable to:				
	Shareholders of the company	49210	38483	27274	137689
	Non-controlling interest	-	-	-	-
13	Paid-up Equity Share Capital (Face Value: Rs.2 per share)	5309	5309	5309	5309
14	Other Equity excluding revaluation reserves				725683
15	Earnings per Share (of Rs.2/- each) (not annualized)				
	a) Basic (Rs.)	18.54	14.62	10.26	51.85
	b) Diluted (Rs.)	18.54	14.62	10.26	51.85



(Handwritten signature)



Contd..

DIVI'S LABORATORIES LIMITED

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2020

NOTES:

1. The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2020 ("Statement") is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors of the Company at its meeting held on 8th August, 2020. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
2. The Consolidated unaudited financial results include the unaudited financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.
3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS108.
4. The Group does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only.
5. Current tax expense includes adjustment of tax reversals of earlier years amounting to Rs. 665 lakhs.
6. The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
7. Forex gain included in Other income / (loss) included in Other expenses for the respective periods is as given below:

	Quarter Ended			Year Ended
	30.06.2020 Rs in lakhs	31.03.2020 Rs. in lakhs	30.06.2019 Rs. in lakhs	31.03.2020 Rs. in lakhs
Forex gain /(loss)	481	5710	(612)	8211

8. *Figures for the quarter ended 31.03.2020 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year.
9. ** Amount is below the rounding norm adopted by the Group
10. Figures for the previous year/period are regrouped or reclassified wherever necessary to conform to current period's classification.

Place: Hyderabad
Date: 8th August, 2020

For Divi's Laboratories Limited

Dr. Murli K. Divi
Managing Director



Price Waterhouse Chartered Accountants LLP

To
The Board of Directors
M/s Divi's Laboratories Limited
Divis Towers, 1-72/23(P)/303
Cyber hills, Gachibowli
Hyderabad, 500032

1. We have reviewed the unaudited consolidated financial results of Divi's Laboratories Limited (the "Parent"), its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group"), [(refer Note [3] on the Statement)] for the quarter ended June 30, 2020 which are included in the accompanying Statement of Consolidated Unaudited financial results for the quarter ended June 30, 2020 (the "Statement"). The Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been stamped by us for identification purposes.
2. This Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Divi's Laboratories (USA) Inc
 - b. Divi's Laboratories Europe AG
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material



Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block E1, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081
T: +91 (40) 4424 6000, F: +91 (40) 4424 6300

Registered office and Head office: Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

6. The consolidated unaudited financial results includes the interim financial results of two subsidiaries which have not been reviewed/audited by their auditors, whose interim financial results reflect total revenue of Rs.9,700 lakhs, total net profit after tax of Rs. 480 lakhs and total comprehensive income of Rs. 491 lakhs for the quarter ended June 30, 2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: FRN 012754N/N500016



Sunit Kumar Basu
Partner

Membership Number 55000

UDIN: 20055000AAAAEW4626

Place: Hyderabad
Date: August 08, 2020

DIVI'S LABORATORIES LIMITED
CIN No. L24110TG1990PLC011854
1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli
Hyderabad – 500 032 Telangana, India
Phone: 23786300 email: cs@divislabs.com

Press Release dated 8th August, 2020

Divi's Labs earns a consolidated total revenue of Rs. 1748 crores for Q1 of FY21

Consolidated Results

Divi's Laboratories has earned a total income of Rs. 1748 crores for the 1st quarter of the year 2020-21 on a consolidated basis, as against an income of Rs. 1193 crores for the corresponding quarter of last year, reflecting a growth of 47%.

Profit before Tax (PBT) for the quarter grew by 77% to Rs. 661 crores as against a PBT of Rs.373 crores for the corresponding quarter of the last year.

The company earned a Profit after Tax (PAT) of Rs. 492 crores for the current quarter as against a PAT of Rs.272 crores for the corresponding quarter of the last year.

Forex gain for the current quarter amounted to Rs. 5 crores as against a loss of Rs. 6 crore during the corresponding quarter of the last year.

The company has been able to have near normal operations during the quarter and there was minimal impact due to covid-19 pandemic. The company has put in place several measures in order to ensure movement, health and safety of employees, supply of materials, production programs/schedules as also dispatches /shipment of finished products to customers, besides helping the community at large and supporting the initiatives of Governments.




Standalone Results

On a standalone basis, the Company's earnings are given below:

₹. in crores

Particulars	For the Quarter	
	30-06-2020	30-06-2019
Total Revenue	1728	1172
PBT	661	366
Tax Expense	169	99
PAT	492	267

Capex projects

While a significant part of the ongoing capex programs has been completed during the last financial year, due to the covid-19 pandemic, there has been delay in implementing the balance part of the capex programs taken up by the company due to non-availability of workmen of some contractors implementing the projects. We have seen improvement subsequently in terms of some of the technicians of contractors reporting for duty and materials arriving at site. We expect to complete the capex programs by second half of the financial year.

